Loading clinical trials...
Loading clinical trials...
Prospective, Single-arm, Single-center Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of Elderly Advanced Triple-positive Breast Cancer.
Conditions
Interventions
Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib
Locations
1
China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
February 1, 2024
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2026
Last Updated
February 1, 2024
NCT07191730
NCT06797635
NCT06312176
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Second Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions